Antithrombotic Strategies in Patients Undergoing Elective Percutaneous Coronary Intervention
Publication
, Journal Article
Rao, SV; Ohman, EM
October 3, 2012
The goals of antithrombotic therapy during percutaneous coronary intervention are to mitigate thrombotic complications associated with iatrogenic plaque disruption from the angioplasty balloon or stent and embolization of thrombotic material from procedural equipment. Available therapies are directed against thrombin and platelets and evidence-based regimens include combinations of unfractionated heparin, low molecular weight heparin, bivalirudin, aspirin, glycoprotein IIb/IIIa inhibitors, and clopidogrel. Data supporting each strategy are presented as are dosing recommendations. © 2013 Blackwell Publishing Ltd.
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Rao, S. V., & Ohman, E. M. (2012). Antithrombotic Strategies in Patients Undergoing Elective Percutaneous Coronary Intervention, 236–245. https://doi.org/10.1002/9781118410875.ch16
Rao, S. V., and E. M. Ohman. “Antithrombotic Strategies in Patients Undergoing Elective Percutaneous Coronary Intervention,” October 3, 2012, 236–45. https://doi.org/10.1002/9781118410875.ch16.
Rao SV, Ohman EM. Antithrombotic Strategies in Patients Undergoing Elective Percutaneous Coronary Intervention. 2012 Oct 3;236–45.
Rao, S. V., and E. M. Ohman. Antithrombotic Strategies in Patients Undergoing Elective Percutaneous Coronary Intervention. Oct. 2012, pp. 236–45. Scopus, doi:10.1002/9781118410875.ch16.
Rao SV, Ohman EM. Antithrombotic Strategies in Patients Undergoing Elective Percutaneous Coronary Intervention. 2012 Oct 3;236–245.